SADC Collaborative Medicines Registration Process (ZAZIBONA) Farai Masekela 13 April 2016
|
|
- Marilyn Gardner
- 5 years ago
- Views:
Transcription
1 SADC Collaborative Medicines Registration Process (ZAZIBONA) Farai Masekela 13 April 2016
2 Presentation Outline Brief Background Terms of Reference Objectives of the Collaborative procedure Progress ZAZIBONA Process The Future
3 Brief Background SADC is a regional economic group with 15 Member States (MS) Varying regulatory capacities in the region 11 MS actively issue marketing authorizations Harmonisation of registration of medicines Directive issued by SADC Ministers of Health in 1999 Work focused on development of technical guidelines (> 22 guidelines developed)
4 The challenge is to achieve balance Access Economic and industrial interests Market Control Public health
5 WHO prequalified Reviews & inspection by each NMRA Duplication of effort #1 Approved by wellresourced Authorities
6 If you want to go quickly, go alone. If you want to go far, go together. ~ African proverb
7 A single stick may smoke, but it will not burn. ~ African proverb
8 Terms of Reference Recognized as TWG under SADC Medicines Regulators Forum Endorsed by Ministers of Health in January 2015 Terms of Reference (ToR) approved by the SADC Ministers of Health 12 Nov 2015 The vision of the ZAZIBONA process in SADC is: a region in which good-quality medicines are available to all those who need them; significantly reduced time taken to grant marketing authorization in the individual countries; and efficient utilization of resources within regional national regulatory through work sharing.
9 Specific Objectives Initiative to collaborate in assessment and inspections for medicines registrations with objectives to: Reduce workload Reduce timelines to registrations Develop mutual trust and confidence in regulatory collaboration Platform for training and collaboration in other regulatory fields
10 Is there anything good in this model?
11 2 Nos. of HoA meetings/year ZAZIBONA: Real Work Sharing in Practice! 7 Training Sessions Since 2013 # of Assessment Joint GMP 10 Sessions: 4 year 2 inspections: 4 year 12 Average # of products per session ZAZIBONA 30% vs 20% Products with positive vs negative recommendation/withdrawn
12 How does this work? Common Submission Essential medicine Manufacturer s Consent Consensus Consolidated Assessment reports (CAR) Consolidated list of Q to applicant (CLOQ) 1 Primary Assessment 4 Countries 4 CAR
13 CAPAs, no reinspection Request additional data from manufacturer CAPAs, re-inspection required Identification of common products List of common products Evaluation of product eligibility Product acceptable? YES Allocation of rapporteurship NO Submission of Applications in 2 or more MS Product not acceptable for evaluation NO Assessment report (AR) Assessment of product dossiers YES Consent provided? Inform and request consent from manufacturer YES Circulation of AR for review GMP inspection required? YES Inspection of manufacturing facility Consolidated AR (CAR) and List of Questions (CLOQ) NO Inspection report YES Consensus on CAR and CLOQ (TC/plenary) More data required? NO Product acceptable? YES GMP compliant? NO NO CAPAs cannot be addressed Recommend approval YES NO Recommend non-approval
14 WHO PQT-m performs QA on the Assessment Reports Outcomes of Assessments and Inspections would be made available (Transparency on Decision Making)
15 What ZAZIBONA is not Replacement of the NMRAs Only focuses on the review and inspection process Actual registration is done at the national level i.e., requires actual submission of product application to the countries following applicable national requirements i.e. application fees etc., Centralised procedure There is no central single submission ( yet) But same dossier submission to all the countries based on the SADC CTD and registration guidelines
16 The future is bright! Sharing Outcomes Participation of others (observers/full participation) Sustainable financing Model can be applicable elsewhere
17 Regulators Manufacturers Patients
18 Acknowledgements ZAZIBONA participating countries DFID Funded SARPAM Programme Co-financing the 2014 Work Plan WHO Prequalification Team Medicines Technical & financial Support SADC Secretariat 4/14/
SADC Collaborative Medicines Registration Initiative (Zazibona)
SADC Collaborative Medicines Registration Initiative (Zazibona) Dr Sinah Selelo Drugs Regulatory Unit Ministry of Health & Wellness GALVmed/OIE stakeholder workshop on the harmonisation of the registration
More informationFeedback on SADC Workshop of Industry & Regulators. Luther Gwaza PhD Consultant
Feedback on SADC Workshop of Industry & Regulators Luther Gwaza PhD Consultant SADC WORKSHOP ON REGISTRATION OF MEDICINES & GOOD MANUFACTURING PRACTICE STANDARDS 11 TH 13 TH APRIL 2016, SOUTH AFRICA Brief
More informationRegulatory Networks. Regulatory Capacity Building Workshop: Vaccine Clinical Trial Review from Ebola to HIV March 2015 Kigali, Rwanda
Regulatory Capacity Building Workshop: Vaccine Clinical Trial Review from Ebola to HIV Regulatory Networks Dr Ahmed Bellah Coordinator Office Regulatory Systems Strengthening [RSS] Regulation of Medicines
More informationTHE AFRICAN MEDICINES REGULATORY HARMONIZATION (AMRH) INITIATIVE Accomplishments, Challenges and Path Forward
THE AFRICAN MEDICINES REGULATORY HARMONIZATION (AMRH) INITIATIVE Accomplishments, Challenges and Path Forward THE AFRICAN MEDICINES REGULATORY HARMONIZATION (AMRH) INITIATIVE Accomplishments, Challenges
More informationICH Regulators Forum. Dr Peter Arlett EU
Dr Peter Arlett EU International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use In this presentation ICH Regulators Forum: Background ICH Regulators
More informationAccelerated procedure for registration of WHO-prequalified medicines = Collaboration Procedure between the WHO Prequalification Programme and NMRAs
Accelerated procedure for registration of WHO-prequalified medicines = Collaboration Procedure between the WHO Prequalification Programme and NMRAs Lembit Rägo/Milan Smid WHO Prequalification of Medicines
More informationAfrican Medicines Registration Harmonisation (AMRH) Initiative: Summary, Status and Future Plans
The New Partnership for Africa s Development (NEPAD) & the World Health Organization (WHO) African Medicines Registration Harmonisation (AMRH) Initiative: Summary, Status and Future Plans The AMRH initiative
More informationRegulatory Conference: KEY TAKE- AWAYS. Engela Dedwith, Eli Lilly
2 nd African Regulatory Conference: KEY TAKE- AWAYS Engela Dedwith, Eli Lilly CONFERENCE TOPICS 1. Regulatory Harmonisation 2. The Global Regulatory Environment 3. The Value of Research and Development
More informationOumkaltoum Lahlou Head of Regulatory Affairs North & West Africa, Merck Group, Darmstadt, Germany
Pharmaceuticals Policy and Law 18 (2016) 99 108 99 DOI 10.3233/PPL-160436 IOS Press Accelerating patient access to medicines in the Economic Community of West African States, the Southern African Development
More informationLEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS
LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS Joey Gouws MCC and Cluster: Food Control, Pharmaceutical Trade and Product Regulation NATIONAL DEPARTMENT OF HEALTH
More informationBEST PRACTICE GUIDE FOR DECENTRALISED AND MUTUAL RECOGNITION PROCEDURES
BEST PRACTICE GUIDE FOR DECENTRALISED AND MUTUAL RECOGNITION PROCEDURES Doc. Ref.: CMDh/068/1996/Rev.10 April 2013 INTRODUCTION 1. Competent authorities should ensure that their assessment reports are
More informationRecent Development of ICH GCG
Recent Development of ICH GCG Japan Pharmaceutical Manufactures Association ICH Project Committee Minoru Kubota, Ph.D. October 12, 2006 APEC 2006, Tokyo JAPAN ICH Objectives Identification and elimination
More informationTrends in the development of regulatory systems by the example of ICH countries
Trends in the development of regulatory systems by the example of ICH countries Author: Pär Tellner, Member of ICH Management Committee (ICH MC), EFPIA * Date: 27/08/2018 * GMP conference, Kazan, Russia
More informationThe place of the Certification procedure in 2017 in the EU regulatory framework and beyond. Prague, 19 September 2017
The place of the Certification procedure in 2017 in the EU regulatory framework and beyond Prague, 19 September 2017 Hélène BRUGUERA Head of the Certification Department, EDQM, Council of Europe CEPs in
More informationUnited Nations Asia-Pacific Regional Coordination Mechanism Terms of Reference
United Nations Asia-Pacific Regional Coordination Mechanism Terms of Reference Thematic Working Group on Resource Efficient Growth (TWG-REG) August 2016 Objectives The objective of the TWG on Resource
More informationCertification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit
Certification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit 01 Training package Why is training needed? Training modules CPP overview CPP scenario training
More informationRegional Update ASEAN PPWG
Regional Update ASEAN by Y uppadee JA V R O O N G R IT, Ph.D. Co-Chair of ACCSQ/, ASEAN Drug Control Division, ThaiFDA, Thailand The ICH-Global Cooperation Group Meeting Radissons SAS Brussels Hotel, Brussels,
More informationRegional Update ASEAN PPWG
Regional Update ASEAN PPWG by Yuppadee JAVROONGRIT, Ph.D. Co-Chair of ACCSQ/PPWG, ASEAN Drug Control Division, ThaiFDA, Thailand The ICH-Global Cooperation Group Meeting Yokohama Royal Park Hotel, Yokohama,
More informationASSESSMENT OF THE CONSOLIDATED ANNUAL ACTIVITY REPORT OF THE AUTHORISING OFFICER FOR THE YEAR 2014
Management Board Decision 07/2015 1(5) ASSESSMENT OF THE CONSOLIDATED ANNUAL ACTIVITY REPORT OF THE AUTHORISING OFFICER FOR THE YEAR 2014 THE MANAGEMENT BOARD, Having regard to Regulation (EC) No 1907/2006
More informationStrengthening Local Pharmaceutical Production in Africa to improve and sustain Access to Medicines
Strengthening Local Pharmaceutical Production in Africa to improve and sustain Access to Medicines Summary A strengthened pharmaceutical industry in Africa will contribute to improved access to new medicines.
More informationThe implementation of the Clinical Trial Regulation (CTR, n 536/2014) in Belgium. and impact on the ethical review process
1 The implementation of the Clinical Trial Regulation (CTR, n 536/2014) in Belgium and impact on the ethical review process 2 1. Clinical Trials on Medicinal Products for Human Use: Change of the Legal
More informationE14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Daniel Bloomfield, MD FACC FAHA Rapporteur, ICH E14 Implementation Working Group PhRMA Topic
More informationOverview of ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
Overview of ICH June 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Legal notice Legal Notice This presentation is protected by copyright and
More informationExpert Review Panel for Diagnostics - Lessons Learnt
Expert Review Panel for Diagnostics - Lessons Learnt Dr. Mariatou Tala Jallow, Head, Sourcing and Procurement of Health Products November 2015 Copenhagen What is the Expert Review Panel for Diagnostics
More informationEvolution and achievements of ICH- GCG (Global Cooperation Group)
Evolution and achievements of ICH- (Global Cooperation Group) Kohei Wada VP/General Manager, Asia Development Dept, Daiichi Sankyo, Japan JPMA representative, ICH Steering Committee & Co-chair, ICH Version
More informationREGIONAL PHARMACEUTICAL FORUM
EAST CENTRAL AND SOUTHERN AFRICA HEALTH COMMUNITY REGIONAL PHARMACEUTICAL FORUM Technical Report of the 9 th Meeting of the Regional Pharmaceutical Forum 5 th -6 th May 2014 - Nairobi, Kenya East Central
More informationCMDv/BPG/002. BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP)
BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP) Edition number: 05 Edition date: 7 November 2013 Implementation date: 6 February 2006 CMDv Secretariat: 7 Westferry Circus, Canary Wharf,
More informationAnnex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions
10 March 2017 Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions Status: Final updated version adopted by the esubmission CMB Scope This annex
More informationCountry Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) Botswana
Country Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) Botswana This document is not a formal publication of WHO and does not necessarily represent the
More informationUse of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland
Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective DIA Europe 2018-17-19 April Basel, Switzerland Presented by Xavier Kurz Head of Service Surveillance and Epidemiology
More informationImplementation of REACH & CLP: common challenges of national authorities and ECHA
Implementation of REACH & CLP: common challenges of national authorities and ECHA Finnish Safety and Chemicals Agency (Tukes); Opening Seminar 9 February 2011, Tampere Geert Dancet Executive Director Content
More informationPHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA 6 TH TECHNICAL COMMITTEE MEETING NOVEMBER 2015 ADDIS ABABA, ETHIOPIA CONCEPT NOTE
PHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA 6 TH TECHNICAL COMMITTEE MEETING 28-29 NOVEMBER 2015 ADDIS ABABA, ETHIOPIA CONCEPT NOTE THEME: PMPA +10: WHERE ARE WE? P a g e 1 1. Background Over the past
More informationLessons from the EMA Patient Registries Initiative
Lessons from the EMA Patient Registries Initiative STAMP Commission Expert Group 8 th June 2018 Presented by Peter Arlett, with contributions from Patricia McGettigan and Jane Moseley Head of Pharmacovigilance
More informationQuestions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards
15 December 2014 EMA/PDCO/179892/2011 Rev. 2 Product Development Scientific Support Paediatric Medicines Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric
More informationMinisterial declaration of the high-level segment submitted by the President of the Council
Ministerial declaration of the high-level segment submitted by the President of the Council Development and international cooperation in the twenty-first century: the role of information technology in
More information1 The EU Harmonised technical ectd guidance version 4.0
Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory ectd format for regulatory submissions (Status: Final version adopted by the esubmission CMB. Dated 26 July 2016) Scope This annex is
More informationPublic health, innovation and intellectual property: global strategy and plan of action
EXECUTIVE BOARD EB126/6 126th Session 3 December 2009 Provisional agenda item 4.3 Public health, innovation and intellectual property: global strategy and plan of action Report by the Secretariat 1. The
More informationLegislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018
Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018 Dr. Rania Bader, HRH2030 Health Workforce Competency Lead HRH2030 The Human Resources for Health (HRH2030) is a
More informationICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY
ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY 1. Opening Discussions The ICH Steering Committee (SC) meeting was chaired by the FDA. The meeting commenced with the provision of
More informationUpdate on FDA-EMA QbD Pilot
Update on FDA-EMA QbD Pilot Presented by: Sharmista Chatterjee, PhD Branch Chief (Acting) Office of Process & Facility Office of Pharmaceutical Quality CDER, FDA Dolores Hernán, PhD Quality Office Specialized
More informationRegional Update ASEAN PPWG
Regional Update ASEAN by Yuppadee JAVROONGRIT, Ph.D. Co-Chair of ACCSQ/, ASEAN Drug Control Division, FDA, Thailand The ICH-Global Cooperation Group Meeting Portland Marriott Downtown Waterfront Hotel,
More informationFORUM FOR EXCHANGE OF INFORMATION ON ENFORCEMENT. Disclaimer:
FORUM FOR EXCHANGE OF INFORMATION ON ENFORCEMENT Adopted at the 9 th meeting of the Forum on 1-3 March 2011 Strategies for enforcement of Regulation (EC) no. 1907/2006 concerning the Registration, Evaluation,
More informationGOING FURTHER TOGETHER
Photo: PATH/Georgina Goodwin GOING FURTHER TOGETHER The case for European Union partnership with Africa on regulatory harmonization GOING FURTHER TOGETHER The case for European Union partnership with Africa
More informationIMDRF FINAL DOCUMENT. Title: Strategic Assessment of Electronic Submission Messaging Formats
IMDRF International Medical Device Regulators Forum FINAL DOCUMENT International Medical Device Regulators Forum Title: Strategic Assessment of Electronic Submission Messaging Formats Authoring Group:
More informationEDQM roadmap for electronic submissions
EDQM roadmap for electronic submissions Cornelia Bigler Weber scientific assistant Certification Department, EDQM 19 September 2017 1 Agenda esubmissions Roadmap for CEP applications with its major changes
More informationMinister s Declaration
Explanatory Memorandum to the code of practice on the role of the director of social services issued under part 8 of the Social Services and Well-being (Wales) Act 2014 This Explanatory Memorandum has
More informationProcedures and Conditions of GLP Registration
Procedures and Conditions of GLP Registration procedures and conditions of GLP registration Third edition October 2015 general criteria for registration Good Laboratory Practice Compliance Monitoring Programme
More information...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS
...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS 1 Table of Contents Pg 3 Pg 4 Pg 5 About Ivowen Limited Meet the team Pharmaceutical Regulatory Affairs Services: Human & Veterinary Pg 5 Pg 5 National Procedures
More information1. New accreditation programmes on the way
In our first issue for 2017, we report on the development of new accreditation programmes, IANZ s search for new board members, working with the Ministry of Business, Innovation & Employment (MBIE) and
More informationRemediation, Resolution and Outcomes
IPA Pharmaceutical Forum 2018 22-23 February 2018 Presented by Andrei Spinei Manufacturing and Quality Compliance, European Medicines Agency An agency of the European Union Contents 1.EMA EU Network 2.Remediation
More information4. Multi Stakeholder: Late & Early Dialogue
4. Multi Stakeholder: Late & Early Dialogue Presented by Spiros Vamvakas on 19 September 2017 Head of Scientific Advice Office An agency of the European Union Background Starting point: Regulators and
More informationPACA Pilot Country Activities Progress Report
PACA Pilot Country Activities Progress Report In 2013, PACA developed its ten year strategy (2013 2022), with input from over 100 stakeholders from agriculture, health, and trade sectors and from across
More informationThe Dublin City Community Enhancement Programme Guidelines 2018
The Dublin City Community Enhancement Programme Guidelines 2018 Please read the following guidelines carefully before completing the Dublin City Community Enhancement Programme Application Form 2018 Introduction
More informationAFRICAN UNION UNION AFRICAINE
AFRICAN UNION UNION AFRICAINE UNIÃO AFRICANA Addis Ababa, ETHIOPIA P. O. Box 3243 Telephone : 011-551 7700 Fax : 011-551 7844 website : www. africa-union.org SECOND SESSION OF THE SPECIALISED TECHNICAL
More informationSample CHO Primary Care Division Quality and Safety Committee. Terms of Reference
DRAFT TITLE: Sample CHO Primary Care Division Quality and Safety Committee Terms of Reference AUTHOR: [insert details] APPROVED BY: [insert details] REFERENCE NO: [insert details] REVISION NO: [insert
More informationEAST AFRICAN COMMUNITY EAST AFRICAN SCIENCE AND TECHNOLOGY COMMISSION (EASTECO)
EAST AFRICAN COMMUNITY EAST AFRICAN SCIENCE AND TECHNOLOGY COMMISSION (EASTECO) TERMS OF REFERENCE FOR CONSULTANCY SERVICES TO FACILITATE ORIENTATION OF EDITORIAL BOARD OF EAST AFRICAN JOURNAL OF SCIENCE,
More informationWork plan for GCP Inspectors Working Group for 2018
22 March 2018 EMA/87812 /2018 Committees and Inspections Chairperson: Ana Rodriguez The activities outlined in the work plan for 2018 have been agreed in view of preparation for the Agency s relocation
More informationINQAAHE Guidelines of Good Practice
INQAAHE Guidelines of Good Practice Procedures Manual 2018 Global enhancement platform for quality assurance providers in higher education 1 P a g e Table of Contents FOREWORD... 3 THE GUIDELINES OF GOOD
More informationPrevention and control of noncommunicable diseases
SIXTY-FIFTH WORLD HEALTH ASSEMBLY A65/8 Provisional agenda item 13.1 22 March 2012 Prevention and control of noncommunicable diseases Implementation of the global strategy for the prevention and control
More informationConsideration on Global Harmonization
ICDRA Workshop I Consideration on Global Harmonization Oct. 25, 2012 Dr. Nobumasa Nakashima Director, Office of International Programs PMDA, Japan 1 Current Harmonization Activities ICH: International
More informationAuditing of Clinical Trials
Version 1.2 Effective date: 3 September 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.2 3 Sept 2012 Version 1.1 12 May
More informationHigh Level Pharmaceutical Forum
High Level Pharmaceutical Forum 2005-2008 Final Conclusions and Recommendations of the High Level Pharmaceutical Forum On 2 nd October 2008, the High Level Pharmaceutical Forum agreed on the following
More informationTopical Peer Review 2017 Ageing Management of Nuclear Power Plants
HLG_p(2016-33)_348 Topical Peer Review 2017 Ageing Management of Nuclear Power Plants Terms of Reference for Topical Peer Review Process This paper provides the terms of reference for the peer review of
More informationAssurance at Country Level: External Audit of Grant Recipients. High Impact Asia Regional Report. GF-OIG August 2013
Assurance at Country Level: External Audit of Grant Recipients High Impact Asia Regional Report 20 August 2013 TABLE OF CONTENTS A. EXECUTIVE SUMMARY... 1 B. MESSAGE FROM THE EXECUTIVE DIRECTOR OF THE
More information14TH CONGRESS OF 9 10 JUNE 2014, GENEVA, ROOM IX, ILO BUILDING
ASSOCIATION INTERNATIONALE DE L INSPECTION DU TRAVAIL INTERNATIONAL ASSOCIATION OF LABOUR INSPECTION ASOCIACION INTERNACIONAL DE L INSPECCION DE TRABAJO INTERNATIONALE VEREINIGUNG FUR ARBEITSINSPEKTION
More informationGeneral Osteopathic Council
General Osteopathic Council Response to the European Commission Consultation regarding Community Action on health services Introduction The General Osteopathic Council (GOsC) is the competent authority
More informationCenter for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Donald D. Ashley, JD 2017 FDLI Enforcement, Litigation, and Compliance Conference: For the Drug,
More informationRegulatory Control of Diagnostics in Tanzania. Hiiti Sillo Ag. Director General Tanzania Food and Drugs Authority
6 th Consultative Stakeholders Meeting on UN PQ of Medicines, Diagnostics and Vaccines 4-5 April, 2011, Geneva, Switzerland Regulatory Control of Diagnostics in Tanzania Hiiti Sillo Ag. Director General
More informationThe Code of Conduct on the Safety of Research Reactors
The Code of Conduct on the Safety of Research Reactors W. Kennedy Research Reactor Safety Section Division of Nuclear Installation Safety Yogyakarta, Indonesia 26/09/2013 International Atomic Energy Agency
More informationMix of civil law and common law. Official law database Ministry for justice, culture and local government of Malta
Malta European Region Updated: February 2017 This document contains links to websites where you can find national legislation and health laws. We link to official government legal sources wherever possible.
More information2009 REPORT ON THE WORK OF THE GLOBAL HEALTH CLUSTER to the Emergency Relief Coordinator from the Chair of the Global Health Cluster.
2009 REPORT ON THE WORK OF THE GLOBAL HEALTH CLUSTER to the Emergency Relief Coordinator from the Chair of the Global Health Cluster Introduction Since the beginning of the implementation of the Humanitarian
More informationTechnical and Financial report-stdf 14. 1am pleased to attach a technical and financial report on STDF 14 which has been duly completed.
ip Organisation Mondiale de la Santé Animale World Organisation for Animal Health Organizaci6n Mundial de Sanidad Animal The Director General Our ref: 06.689 DS/NM Paris, 23 November 2006 Mr Michael Roberts
More informationYour guide to the National Standards for Safer Better Maternity Services
Your guide to the National Standards for Safer Better Maternity Services Safer Better Care December 2016 Table of Contents About this guide...2 What is HIQA?...2 What are maternity services?...3 Why did
More informationAssurance at Country Level: External Audit of Grant Recipients. High Impact Africa 2 Regional Report. GF-OIG August 2013
Assurance at Country Level: External Audit of Grant Recipients High Impact Africa 2 Regional Report 20 August 2013 TABLE OF CONTENTS A. EXECUTIVE SUMMARY... 1 B. MESSAGE FROM THE EXECUTIVE DIRECTOR OF
More informationDocumenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC
Documenting the Story of a Clinical Trial: Concept to CAPA Lori T. Gilmartin Gilmartin Consulting LLC The regulations represent the floor while ethical thinking is the sky. Dr. Thomas Moore Boston University
More informationJICA s Institutional and Human Capacity Building toward SADC s DFI together with SADC-DFRC
JICA s Institutional and Human Capacity Building toward SADC s DFI together with SADC-DFRC December, 2014 JICA South Africa Office Representative Masao SHINO Table of Contents 1.JICA s Activities 2.JICA
More informationTERMS OF REFERENCE (ToR) FOR NATIONAL AGRO- PROCESSING FORUM
TERMS OF REFERENCE (ToR) FOR NATIONAL AGRO- PROCESSING FORUM 1 Table of Contents 1. INTRODUCTION AND BACKGROUND... 3 2. NAME OF THE FORUM... 3 3. PURPOSE OF THE FORUM... 4 4. ROLE AND SCOPE OF THE FORUM...
More informationCountry Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) ANGOLA
Country Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) ANGOLA 1 Outline of the Profile Introduction p. 3 Part 1- Health and Demographic Data.. p. 4 Part
More informationNZQA registered unit standard version 1 Page 1 of 6. Conduct asbestos assessment associated with removal
Page 1 of 6 Title Conduct asbestos assessment associated with removal Level 6 Credits 5 Purpose This unit standard specifies the Outcomes required to act as an Assessor for removal of friable asbestos
More informationCommission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo
Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics 30.1.2017 Oslo 3.2.2017 O. Konttinen 1 Background Based on directive 2001/20/EC of the clinical trials on medicinal
More informationOutsourcing biopharmaceuticals manufacturing Best practices when working with external supply partners
Outsourcing biopharmaceuticals manufacturing Best practices when working with external supply partners Dr. Ulrich Rümenapp, Bayer AG Biologics & Biosimilars Congress 1-2 February 2016 Berlin, Germany Outline
More informationSubmission to the OIE for official recognition of FMD country status and endorsement of official control programme
Submission to the OIE for official recognition of FMD country status and endorsement of official control programme L. Weber-Vintzel & J. Domenech OIE, Paris GF-TADs FMD Working Group Members What are the
More informationPLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS
PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS In August 2010, the Food and Drug Administration s Center for Devices and Radiological Health (CDRH or the Center) released for public
More informationSouth West Portugal/Spain FAB Initiative Annual SW FAB Report Annual SW FAB Report Page 1 of 16
Page 1 of 16 This page is left intentionally blank for printing purposes Page 2 of 16 REPORT DOCUMENTATION PAGE TITLE OF THE DOCUMENT: AUTHOR(S): Council; Supervisory Authority Committee (SAC); Operational
More information2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations
2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and
More informationCountry Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) Zimbabwe
Country Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) This document is not a formal publication of WHO and does not necessarily represent the decisions
More informationMarket Access for Food Supplements: EHPM Country Profiles. Mr Patrick Ahern Director General EHPM
Market Access for Food Supplements: EHPM Country Profiles Mr Patrick Ahern Director General EHPM EHPM European federation of National Associations of Health Product Manufacturers Established 1975, 13 members,
More informationGood Laboratory Practices Why all the fuss?
Good Laboratory Practices Why all the fuss? Ray McAllister, Ph.D. Senior Director, Regulatory Policy CropLife America NAICC 2013 Annual meeting January 24, 2012 Jacksonville, FL What is CropLife America?
More informationFresh Water Iwi Leaders Group. Te Mana o te Wai
Te Mana o te Wai IAG/ILG/ICF This is not the Maori view, however it is a representation of key directions supported by the ICF and there will be multiple views on this across Maoridom. Iwi Chairs Forum
More informationBETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS
A2 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS March 2012 A3 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI) FIFTH REPORT ON PROGRESS Chief Executive s foreword In January
More informationIn 2012, the Regional Committee passed a
Strengthening health systems for universal health coverage In 2012, the Regional Committee passed a resolution endorsing a proposed roadmap on strengthening health systems as a strategic priority, as well
More informationREGISTRATION OF MEDICINES IN THE EURASIAN ECONOMIC UNION
REGISTRATION OF MEDICINES IN THE EURASIAN ECONOMIC UNION www.gratanet.com At the Pharmaceutical Forum of the EAEU and CIS countries held in Moscow in late February 2018, the Director of the Department
More informationCountry Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) Malawi
Country Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC) Malawi This document is not a formal publication of WHO and does not necessarily represent the
More informationConnie Hoy October 2013
Connie Hoy October 2013 Warning letter issued to firm for complaint handling Failure to report within 30 days Failure to implement adequate procedures Failure to establish standard review process No procedure
More informationWhite Paper. WHO assessment of vaccines regulatory system: Proposal for establishment of maturity level concept
1. Working group members A working group had been set up including the following country regulatory experts: Australia: Chris Rolls, Therapeutic Goods Administration (TGA) Cuba: Celeste Sánchez, Centro
More informationsupplementary criteria for GLP registration
supplementary criteria for GLP registration GLP Compliance Monitoring Programme Equipment Calibration and Traceability of Measurement Second edition October 2007 supplementary criteria for GLP registration
More informationQuality Risk Management ICH Q9
Quality Risk Management ICH Q9 Executive summary for competent authorities and industry Disclaimer: This presentation includes the author s views on quality risk management theory and practice. The presentation
More informationSCOPE OF WORK AND APPLICATION GUIDELINES. Investment Promotion Advisor. Tanzania Investment Center
SCOPE OF WORK AND APPLICATION GUIDELINES Investment Promotion Advisor Tanzania Investment Center 1). Background The East Africa Trade and Investment Hub (the Hub) is the U.S. Government s flagship project
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number End of Study Report SOP-RES-027 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s) Natalie
More informationThe hallmarks of the Global Community Engagement and Resilience Fund (GCERF) Core Funding Mechanism (CFM) are:
(CFM) 1. Guiding Principles The hallmarks of the Global Community Engagement and Resilience Fund (GCERF) Core Funding Mechanism (CFM) are: (a) Impact: Demonstrably strengthen resilience against violent
More information